Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To assess the evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between years 2000 and 2021.
Methods: Pediatric patients (≤ 16 years) referred for 18F-FDG PET/CT or PET/MR imaging of the body during 2000 and 2021 were retrospectively included. The amount of administered radiotracer activity in megabecquerel (MBq) was recorded, and signal-to-noise ratio (SNR) was measured in the right liver lobe with a 4 cm volume of interest as an indicator for objective image quality. Descriptive statistics were computed.
Results: Two hundred forty-three children and adolescents underwent a total of 466 examinations. The median injected 18F-FDG activity in MBq decreased significantly from 296 MBq in 2000-2005 to 100 MBq in 2016-2021 (p < 0.001), equaling approximately one-third of the initial amount. The median SNR ratio was stable during all years with 11.7 (interquartile range [IQR] 10.7-12.9, p = 0.133).
Conclusions: Children have benefited from a massive reduction in the administered 18F-FDG dose over the past 20 years without compromising objective image quality.
Clinical Relevance Statement: Radiotracer dose was reduced considerably over the past two decades of pediatric F-18-fluorodeoxyglucose PET/CT and PET/MR imaging highlighting the success of technical innovations in pediatric PET imaging.
Key Points: • The evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between 2000 and 2021 was assessed. • The injected tracer activity decreased by 66% during the study period from 296 megabecquerel (MBq) to 100 MBq (p < 0.001). • The continuous implementation of technical innovations in pediatric hybrid 18F-FDG PET has led to a steady decrease in the amount of applied radiotracer, which is particularly beneficial for children who are more sensitive to radiation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126459 | PMC |
| http://dx.doi.org/10.1007/s00330-023-10319-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia.
Eur J Nucl Med Mol Imaging
August 2025
Unit of Nuclear Medicine, Department of Medicine -DIMED, University Hospital of Padua, Padova, Italy.
Background: Primary ciliary dyskinesia (PCD) is a rare condition characterized by ciliary dysfunction, impaired mucociliary clearance and mucus accumulation in the airways.
Purpose: Our aim was to evaluate the performance of [18F]FDG PET/MR in assessing structural and inflammatory pulmonary features in patients with PCD, using high-resolution CT (HRCT) as the gold-standard reference.
Materials And Methods: We recruited patients with PCD (≥ 7 years) regularly followed at our Regional Center for PCD.
Evaluating the Diagnostic Performance of PET/MR Versus CECT in Determining Resectability in Ovarian Cancer.
Cancers (Basel)
August 2025
Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX 77030, USA.
This study aimed to compare the diagnostic accuracy of whole-body PET/MR imaging and contrast-enhanced CT for detecting metastatic disease in patients undergoing surgical resection, using pathology as the reference standard. Nineteen patients with suspected metastatic involvement (including four who received neoadjuvant therapy before surgery) underwent both FDG PET/MR and contrast-enhanced CT scans. Imaging was reviewed for metastases at defined sites (e.
View Article and Find Full Text PDFComparative study on the diagnostic value of F-FDG PET/CT imaging and integrated PET/MR imaging in pediatric tumors.
Hell J Nucl Med
August 2025
Pediatric Department, Taizhou People's Hospital, Taizhou, China.
Objective: To analyze and compare the diagnostic value of fluorine-18-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) imaging and integrated PET/magnetic resonance imaging (MR) in pediatric tumors.
Subjects And Methods: A retrospective analysis was conducted on the clinical data of 61 pediatric patients with malignant tumors admitted to our hospital from September 2022 to December 2023. All patients underwent pathological examinations as well as F-FDG PET/CT and integrated PET/MR imaging.
Synergizing Liquid Biopsy and Hybrid PET Imaging for Prognostic Assessment in Prostate Cancer: A Focus Review.
Biomolecules
July 2025
Academic Radiology, Department of Surgical, Medical, Molecular Pathology and Emergency Medicine, University of Pisa, 56126 Pisa, Italy.
Positron emission tomography (PET) and liquid biopsy have independently transformed prostate cancer management. This review explores the complementary roles of PET imaging and liquid biopsy in prostate cancer, focusing on their combined diagnostic, monitoring, and prognostic potential. A systematic search of PubMed, Scopus, and Cochrane Library databases was conducted to identify human studies published in English up to January 2025.
View Article and Find Full Text PDFIn vivo 3D myocardial membrane potential mapping in humans using PET/MRI.
EJNMMI Res
July 2025
Yale Biomedical Imaging Institute, Yale University School of Medicine, New Haven, CT, USA.
Background: The mitochondrial membrane potential is a key biophysical parameter of mitochondrial function, which can be useful for the diagnosis and treatment monitoring of various cardiac diseases. We present a non-invasive PET/MR imaging method for 3D myocardial membrane potential mapping in humans.
Results: An in vivo PET/MR imaging study was performed in three healthy subjects (1 male and 2 females; 48 ± 29 years old) under a study protocol approved by the local Institutional Review Board (IRB).